<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="673">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04322682</url>
  </required_header>
  <id_info>
    <org_study_id>MHIPS-2020-001</org_study_id>
    <secondary_id>3R01HL146206-02S1</secondary_id>
    <nct_id>NCT04322682</nct_id>
  </id_info>
  <brief_title>Colchicine Coronavirus SARS-CoV2 Trial (COLCORONA)</brief_title>
  <acronym>COVID-19</acronym>
  <official_title>Colchicine Coronavirus SARS-CoV2 Trial (COLCORONA)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Montreal Heart Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bill and Melinda Gates Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Government of Quebec</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>DACIMA Software</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Montreal Heart Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase 3, randomized, double-blind, placebo-controlled multicenter study to evaluate&#xD;
      the efficacy and safety of colchicine in adult patients diagnosed with COVID-19 infection and&#xD;
      have at least one high-risk criterion. Approximately 6000 subjects meeting all inclusion and&#xD;
      no exclusion criteria will be randomized to receive either colchicine or placebo tablets for&#xD;
      30 days.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of this study is to determine whether short-term treatment with&#xD;
      colchicine reduces the rate of death and lung complications related to COVID-19. The&#xD;
      secondary objective is to determine the safety of treatment with colchicine in this patient&#xD;
      population.&#xD;
&#xD;
      Approximately 6000 patients will be enrolled to receive either colchicine or placebo (1:1&#xD;
      allocation ratio) for 30 days. Follow-up assessments will occur at 15 and 30 days following&#xD;
      randomization for evaluation of the occurrence of any trial endpoints or other adverse&#xD;
      events.&#xD;
&#xD;
      Safety and efficacy will be based on data from randomized patients. An independent data and&#xD;
      safety monitoring board (DSMB) will periodically review study results as well as the overall&#xD;
      conduct of the study, and will make recommendations to the study Executive Steering Committee&#xD;
      (ESC) to continue, stop or modify the study protocol.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 23, 2020</start_date>
  <completion_date type="Actual">January 21, 2021</completion_date>
  <primary_completion_date type="Actual">January 21, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This will be a randomized, double-blind, placebo-controlled, multi-center study. Following signature of the informed consent form, approximately 6000 subjects meeting all inclusion and no exclusion criteria will be randomized to receive either colchicine or placebo (1:1 allocation ratio) for 30 days. Follow-up phone or video assessments will occur at 15 and 30 days following randomization for evaluation of the occurrence of any trial endpoints or other adverse events.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants who die or require hospitalization due to COVID-19 infection</measure>
    <time_frame>30 days post randomization</time_frame>
    <description>The primary endpoint will be the composite of death or the need for hospitalization due to COVID-19 infection in the first 30 days after randomization.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants who die</measure>
    <time_frame>30 days post randomization</time_frame>
    <description>The secondary endpoint is the occurrence of death in the 30 days following randomization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants requiring hospitalization due to COVID-19 infection</measure>
    <time_frame>30 days post randomization</time_frame>
    <description>The secondary endpoint is the need for hospitalization due to COVID-19 infection in the 30 days following randomization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants requiring mechanical ventilation</measure>
    <time_frame>30 days post randomization</time_frame>
    <description>The secondary endpoint is the need for mechanical ventilation in the 30 days following randomization.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">4506</enrollment>
  <condition>Corona Virus Infection</condition>
  <arm_group>
    <arm_group_label>Colchicine 0.5 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive study medication colchicine 0.5 mg per os (PO) twice daily for the first 3 days and then once daily for the last 27 days. If a dose is missed, it should not be replaced.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients will receive a placebo per os (PO) twice daily for the first 3 days and then once daily for the last 27 days. If a dose is missed, it should not be replaced.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Colchicine</intervention_name>
    <description>Patients in this arm will receive study medication colchicine 0.5 mg per os (PO) twice daily for the first 3 days and then once daily for the last 27 days. If a dose is missed, it should not be replaced.</description>
    <arm_group_label>Colchicine 0.5 mg</arm_group_label>
    <other_name>Immuno-modulatory</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo oral tablet</intervention_name>
    <description>Patients will receive the placebo 0.5 mg per os (PO) twice daily for the first 3 days and then once daily for the last 27 days. If a dose is missed, it should not be replaced.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Males and females, at least 40 years of age, capable and willing to provide informed&#xD;
             consent;&#xD;
&#xD;
          2. Patient must have received a diagnosis of COVID-19 infection within the last 24 hours;&#xD;
&#xD;
          3. Outpatient setting (not currently hospitalized or under immediate consideration for&#xD;
             hospitalization);&#xD;
&#xD;
          4. Patient must possess at least one of the following high-risk criteria: 70 years or&#xD;
             more of age, obesity (BMI ≥ 30 kg/m2), diabetes mellitus, uncontrolled hypertension&#xD;
             (systolic blood pressure ≥150 mm Hg), known respiratory disease (including asthma or&#xD;
             chronic obstructive pulmonary disease), known heart failure, known coronary disease,&#xD;
             fever of ≥38.4°C within the last 48 hours, dyspnea at the time of presentation,&#xD;
             bicytopenia, pancytopenia, or the combination of high neutrophil count and low&#xD;
             lymphocyte count;&#xD;
&#xD;
          5. Female patient is either not of childbearing potential, defined as postmenopausal for&#xD;
             at least 1 year or surgically sterile, or is of childbearing potential and practicing&#xD;
             at least one method of contraception and preferably two complementary forms of&#xD;
             contraception including a barrier method (e.g. male or female condoms, spermicides,&#xD;
             sponges, foams, jellies, diaphragm, intrauterine device (IUD)) throughout the study&#xD;
             and for 30 days after study completion;&#xD;
&#xD;
          6. Patient must be able and willing to comply with the requirements of this study&#xD;
             protocol.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patient currently hospitalized or under immediate consideration for hospitalization;&#xD;
&#xD;
          2. Patient currently in shock or with hemodynamic instability;&#xD;
&#xD;
          3. Patient with inflammatory bowel disease (Crohn's disease or ulcerative colitis),&#xD;
             chronic diarrhea or malabsorption;&#xD;
&#xD;
          4. Patient with pre-existent progressive neuromuscular disease;&#xD;
&#xD;
          5. Estimated Glomerular filtration rate (eGFR), using the MDRD equation for all subjects&#xD;
             being considered for enrollment, with a cut-off of &lt; 30 mL/m in/1.73m2;&#xD;
&#xD;
          6. Patient with a history of cirrhosis, chronic active hepatitis or severe hepatic&#xD;
             disease;&#xD;
&#xD;
          7. Female patient who is pregnant, or breast-feeding or is considering becoming pregnant&#xD;
             during the study or for 6 months after the last dose of study medication;&#xD;
&#xD;
          8. Patient currently taking colchicine for other indications (mainly chronic indications&#xD;
             represented by Familial Mediterranean Fever or gout);&#xD;
&#xD;
          9. Patient with a history of an allergic reaction or significant sensitivity to&#xD;
             colchicine;&#xD;
&#xD;
         10. Patient undergoing chemotherapy for cancer;&#xD;
&#xD;
         11. Patient is considered by the investigator, for any reason, to be an unsuitable&#xD;
             candidate for the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Claude Tardif, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Montreal Heart Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Zohar Bassevitch, B.SC.</last_name>
    <role>Study Director</role>
    <affiliation>Montreal Health Innovations Coordinating Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic - Arizona</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85054</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yuma Regional Medical Center Cancer Center</name>
      <address>
        <city>Yuma</city>
        <state>Arizona</state>
        <zip>85364</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Arkansas for medical Sciences</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centric Health Resources Inc.</name>
      <address>
        <city>Bakersfield</city>
        <state>California</state>
        <zip>93308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Westside Medical Associates of Los Angeles</name>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <zip>90211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rancho Research Institute</name>
      <address>
        <city>Downey</city>
        <state>California</state>
        <zip>90242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California, San Francisco - San Francisco General Hospital</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic - Jacksonville</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South Florida Research Organization</name>
      <address>
        <city>Medley</city>
        <state>Florida</state>
        <zip>33166</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Miami Center for Advanced Cardiology</name>
      <address>
        <city>Miami Beach</city>
        <state>Florida</state>
        <zip>33140</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic - Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Mississippi Medical Clinics, Inc.</name>
      <address>
        <city>Tupelo</city>
        <state>Mississippi</state>
        <zip>38801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York University School of Medecine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of North Carolina at Chapel Hill</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prisma Health</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor Scott &amp; White Research Institute - Pharmacy</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas(UT) Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spring Clinical Research</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77002</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Heart Institute (inCor), Scholl of Medecine, University of Sao Paulo</name>
      <address>
        <city>São Paulo</city>
        <state>Sao Paulo</state>
        <zip>05403-900</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montreal Heart Institute</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H1T 1C8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tread Research, Tygerberg Hospital</name>
      <address>
        <city>Cape Town</city>
        <zip>7500</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz, IdiPaz</name>
      <address>
        <city>La Paz</city>
        <state>Madrid</state>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
    <country>Canada</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>March 23, 2020</study_first_submitted>
  <study_first_submitted_qc>March 25, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 26, 2020</study_first_posted>
  <last_update_submitted>January 21, 2021</last_update_submitted>
  <last_update_submitted_qc>January 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronavirus Infections</mesh_term>
    <mesh_term>Severe Acute Respiratory Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colchicine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

